Table 7.

CSF findings at the time of the first LP and at the time of follow-up

	Units	First LP ever	Follow-up LPs, first LP/event
Pleocytosis, all acute attacks	Samples	44/79 (55.7%)	10/23 (43.5%)
Pleocytosis, acute MY	Samples	26/31 (83.9%)	6/9 (66.7%)
Pleocytosis, acute ON	Samples	12/39 (30.8%)	3/11 (27.3%)
Pleocytosis, acute BRAIN	Samples	5/7 (71.4%)	1/3 (33.3%)
OCB, all acute attacks	Samples	7/73 (9.6%)	2/23 (8.7%)
OCB, acute MY	Samples	1/27 (3.7%)	2/10 (20%)#
OCB, acute ON	Samples	3/38 (7.9%)	0/10 (0%)
OCB, acute BRAIN	Samples	2/7 (28.6%)	0/3 (0%)
IgG-IF > 10%, all acute attacks	Samples	4/63 (6.3%)	3/24 (12.5%)
IgG-IF > 10%, acute MY	Samples	2/26 (7.7%)	0/9 (0%)
IgG-IF > 10%, acute ON	Samples	2/31 (6.5%)	0/9 (0%)
IgG-IF > 10%, acute BRAIN	Samples	0/5 (0%)	0/3 (0%)
QAlb > Qlim(Alb), all acute attacks	Samples	35/65 (53.8%)	7/23 (30.4%)
QAlb > Qlim(Alb), acute MY	Samples	16/26 (61.5%)	6/10 (60%)
QAlb > Qlim(Alb), acute ON	Samples	14/33 (42.4%)	1/10 (10%)
QAlb > Qlim(Alb), acute BRAIN	Samples	4/5 (80%)	0/3 (0%)
CSF TP elevated, all acute attacks	Samples	33/70 (47.1%)	9/23 (39.1%)
CSF TP elevated, acute MY	Samples	15/27 (55.6%)	6/10 (60%)
CSF TP elevated, acute ON	Samples	14/37 (37.8%)	1/10 (10%)
CSF TP elevated, acute BRAIN	Samples	4/5 (80%)	2/3 (66.7%)
CSF l-lactate elevated, all acute attacks	Samples	14/52 (26.9%)	2/13 (15.4%)
CSF l-lactate elevated, acute MY	Samples	9/21 (42.9%)	1/5 (20%)
CSF l-lactate elevated, acute ON	Samples	5/28 (17.9%)	1/8 (12.5%)
CSF l-lactate elevated, acute BRAIN	Samples	0/3 (0%)	0/0 (0%)
Time since attack onset, acute LPs	Days	7 (0-34)	9.5 (0-28)

To control for the fact that the number of CSF samples obtained per event differed among patients in the subgroup with follow-up LPs, only the first LP obtained during each attack was taken into account for this analysis

IgG-IF intrathecal IgG fraction; OCB oligoclonal bands; QAlb CSF/serum albumin quotient; TP total protein; WCC white cell count

^#p = n.s.